Zentalis Pharmaceuticals, Inc. Income Statement
ZNTL|2 years of annual SEC 10-K data (FY2024-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
Zentalis Pharmaceuticals, Inc. reported $0 in revenue and $292M in net loss for FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Revenue | $0 | $0 |
| SG&A Expense | $64.4M | $54.6M |
| R&D Expense | $189.6M | $172.7M |
| Operating Income | -$299.5M | -$227.3M |
| Income Tax | -$601.0K | -$469.0K |
| Net Income | -$292.2M | -$236.8M |
| EPS (Basic) | -$4.47 | -$4.48 |
| EPS (Diluted) | -$4.47 | -$4.48 |
| Shares Outstanding | 71.3M | 70.8M |